Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
11.37 ^USD	-4.85%		+45.58%	-7.11%

20/05	Pulse Biosciences Moves New Record Date for Rights Offering	MT
14/05	Pulse Biosciences Appoints Burke Barrett as President, CEO	MT

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

January 11, 2022 at 05:30 pm IST

Pulse Biosciences, Inc. provided revenue guidance for the fourth quarter 2021. Preliminary unaudited full year 2021 revenue is expected to be in the range of $1.3 million to $1.4 million, including preliminary unaudited fourth quarter 2021 revenue of approximately $750,000.

Latest news about Pulse Biosciences, Inc.

Pulse Biosciences Moves New Record Date for Rights Offering	21/05	MT
Pulse Biosciences Appoints Burke Barrett as President, CEO	15/05	MT
Pulse Biosciences, Inc Announces CEO Changes	15/05	CI
Pulse Biosciences, Inc Announces Executive Changes	15/05	CI
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	09/05	CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Sector Update: Health Care Stocks Slide Late Afternoon	02/04	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	29/03
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Sector Update: Health Care Stocks Ease Late Afternoon	09/03	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	09/03	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02	CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	20/12	CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	14/12	MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	01/12	MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan	28/11	DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	28/11	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	22/11	MT

Chart Pulse Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Sector

Advanced Medical Equipment & Technology

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
PULSE BIOSCIENCES, INC.	-7.11%	628M
THERMO FISHER SCIENTIFIC	+10.03%	223B
DANAHER CORPORATION	+13.59%	195B
INTUITIVE SURGICAL, INC.	+20.01%	144B
BOSTON SCIENTIFIC CORPORATION	+30.83%	111B
SIEMENS HEALTHINEERS AG	+2.05%	65.01B
EDWARDS LIFESCIENCES CORPORATION	+15.38%	53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	50.45B
AGILENT TECHNOLOGIES, INC.	+8.37%	44.15B
GE HEALTHCARE TECHNOLOGIES INC.	+3.27%	36.45B

Other Advanced Medical Equipment & Technology